Surgical treatment of gastroentero-pancreatic neuroendocrine tumor

Ohtsuka Takao, Shunichi Takahata, Junji Ueda, Takashi Ueki, Eishi Nagai, Kazuhiro Mizumoto, Shuji Shimizu, Masao Tanaka

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The treatment of choice for gastroentero-pancreatic neuroendocrine tumor (NET) is resection. Because it is difficult to determine the histological grade of NET before operation, the treatment strategy is usually made based on an imaging study including the tumor's size. Some selected gastrointestinal NETs are indicated for endoscopic resection, while others are resected surgically with lymph node dissection. The types of resections for pancreatic NETs vary from enucleation to pancreatectomy with or without regional lymph node dissection, based on the type of excessive hormone, tumor size, distance from the main pancreatic duct, and the presence of type 1 multiple endocrine neoplasia. Hepatic metastases are also resected, if indicated, and even in patients having unresectable metastatic lesions, multidisciplinary therapy including reduction surgery of over 90% of tumor volume might lead to a favorable prognosis. Postoperative adjuvant therapy is recommended for neuroendocrine carcinoma, while there is no evidence to support adjuvant therapy for curatively resected well-differentiated NET.

Original languageEnglish
Pages (from-to)843-846
Number of pages4
JournalJapanese Journal of Cancer and Chemotherapy
Volume40
Issue number7
Publication statusPublished - Jan 1 2013

Fingerprint

Neuroendocrine Tumors
Lymph Node Excision
Multiple Endocrine Neoplasia Type 1
Therapeutics
Neuroendocrine Carcinoma
Pancreatectomy
Pancreatic Ducts
Tumor Burden
Neoplasms
Hormones
Neoplasm Metastasis
Liver

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Takao, O., Takahata, S., Ueda, J., Ueki, T., Nagai, E., Mizumoto, K., ... Tanaka, M. (2013). Surgical treatment of gastroentero-pancreatic neuroendocrine tumor. Japanese Journal of Cancer and Chemotherapy, 40(7), 843-846.

Surgical treatment of gastroentero-pancreatic neuroendocrine tumor. / Takao, Ohtsuka; Takahata, Shunichi; Ueda, Junji; Ueki, Takashi; Nagai, Eishi; Mizumoto, Kazuhiro; Shimizu, Shuji; Tanaka, Masao.

In: Japanese Journal of Cancer and Chemotherapy, Vol. 40, No. 7, 01.01.2013, p. 843-846.

Research output: Contribution to journalArticle

Takao, Ohtsuka ; Takahata, Shunichi ; Ueda, Junji ; Ueki, Takashi ; Nagai, Eishi ; Mizumoto, Kazuhiro ; Shimizu, Shuji ; Tanaka, Masao. / Surgical treatment of gastroentero-pancreatic neuroendocrine tumor. In: Japanese Journal of Cancer and Chemotherapy. 2013 ; Vol. 40, No. 7. pp. 843-846.
@article{593083f1110c4be8acd01357d9fd1686,
title = "Surgical treatment of gastroentero-pancreatic neuroendocrine tumor",
abstract = "The treatment of choice for gastroentero-pancreatic neuroendocrine tumor (NET) is resection. Because it is difficult to determine the histological grade of NET before operation, the treatment strategy is usually made based on an imaging study including the tumor's size. Some selected gastrointestinal NETs are indicated for endoscopic resection, while others are resected surgically with lymph node dissection. The types of resections for pancreatic NETs vary from enucleation to pancreatectomy with or without regional lymph node dissection, based on the type of excessive hormone, tumor size, distance from the main pancreatic duct, and the presence of type 1 multiple endocrine neoplasia. Hepatic metastases are also resected, if indicated, and even in patients having unresectable metastatic lesions, multidisciplinary therapy including reduction surgery of over 90{\%} of tumor volume might lead to a favorable prognosis. Postoperative adjuvant therapy is recommended for neuroendocrine carcinoma, while there is no evidence to support adjuvant therapy for curatively resected well-differentiated NET.",
author = "Ohtsuka Takao and Shunichi Takahata and Junji Ueda and Takashi Ueki and Eishi Nagai and Kazuhiro Mizumoto and Shuji Shimizu and Masao Tanaka",
year = "2013",
month = "1",
day = "1",
language = "English",
volume = "40",
pages = "843--846",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "7",

}

TY - JOUR

T1 - Surgical treatment of gastroentero-pancreatic neuroendocrine tumor

AU - Takao, Ohtsuka

AU - Takahata, Shunichi

AU - Ueda, Junji

AU - Ueki, Takashi

AU - Nagai, Eishi

AU - Mizumoto, Kazuhiro

AU - Shimizu, Shuji

AU - Tanaka, Masao

PY - 2013/1/1

Y1 - 2013/1/1

N2 - The treatment of choice for gastroentero-pancreatic neuroendocrine tumor (NET) is resection. Because it is difficult to determine the histological grade of NET before operation, the treatment strategy is usually made based on an imaging study including the tumor's size. Some selected gastrointestinal NETs are indicated for endoscopic resection, while others are resected surgically with lymph node dissection. The types of resections for pancreatic NETs vary from enucleation to pancreatectomy with or without regional lymph node dissection, based on the type of excessive hormone, tumor size, distance from the main pancreatic duct, and the presence of type 1 multiple endocrine neoplasia. Hepatic metastases are also resected, if indicated, and even in patients having unresectable metastatic lesions, multidisciplinary therapy including reduction surgery of over 90% of tumor volume might lead to a favorable prognosis. Postoperative adjuvant therapy is recommended for neuroendocrine carcinoma, while there is no evidence to support adjuvant therapy for curatively resected well-differentiated NET.

AB - The treatment of choice for gastroentero-pancreatic neuroendocrine tumor (NET) is resection. Because it is difficult to determine the histological grade of NET before operation, the treatment strategy is usually made based on an imaging study including the tumor's size. Some selected gastrointestinal NETs are indicated for endoscopic resection, while others are resected surgically with lymph node dissection. The types of resections for pancreatic NETs vary from enucleation to pancreatectomy with or without regional lymph node dissection, based on the type of excessive hormone, tumor size, distance from the main pancreatic duct, and the presence of type 1 multiple endocrine neoplasia. Hepatic metastases are also resected, if indicated, and even in patients having unresectable metastatic lesions, multidisciplinary therapy including reduction surgery of over 90% of tumor volume might lead to a favorable prognosis. Postoperative adjuvant therapy is recommended for neuroendocrine carcinoma, while there is no evidence to support adjuvant therapy for curatively resected well-differentiated NET.

UR - http://www.scopus.com/inward/record.url?scp=84884474094&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884474094&partnerID=8YFLogxK

M3 - Article

C2 - 23863724

AN - SCOPUS:84884474094

VL - 40

SP - 843

EP - 846

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 7

ER -